Delving into the Latest Updates on IN05 (In3Bio) with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms-

Target-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Colorectal Cancer

Inactive Indication-

Originator Organization

In3Bio Ltd.

Active Organization

In3Bio Ltd.

Inactive Organization-

Drug Highest PhaseEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

Developing anti-parasitic lead compounds that act on key vulnerabilities are necessary for new anti-infectives. Malaria, leishmaniasis, toxoplasmosis, cryptosporidiosis and coccidiosis together kill >500,000 humans annually. Their causative parasites Plasmodium, Leishmania, Toxoplasma, Cryptosporidium and Eimeria display high conservation in many housekeeping genes, suggesting that these parasites can be attacked by targeting invariant essential proteins. Here, we describe selective and potent inhibition of prolyl-tRNA synthetases (PRSs) from the above parasites using a series of quinazolinone-scaffold compounds. Our PRS-drug co-crystal structures reveal remarkable active site plasticity that accommodates diversely substituted compounds, an enzymatic feature that can be leveraged for refining drug-like properties of quinazolinones on a per parasite basis. A compound we termed In-5 exhibited a unique double conformation, enhanced drug-like properties, and cleared malaria in mice. It thus represents a new lead for optimization. Collectively, our data offer insights into the structure-guided optimization of quinazolinone-based compounds for drug development against multiple human eukaryotic pathogens.

100 Deals associated with IN05 (In3Bio)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colorectal Cancer	Phase 1	GB	In3Bio Ltd.	30 Mar 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCLC2023 Manual	Phase 1	Non-small cell lung cancer stage III Neoadjuvant	9	radiotherapy 10 Gy in 5 fractions+Durvalumab+Chemotherapy	(fsleprtwil) = Grade 3-4 AEs were reported in 3 (33.3%) patients, including leukopenia (22.2%), anemia (11.1%), and infectious pneumonia (11.1%). ugtzlscdrq (ayjdfrhvaj ) View more	Positive	12 Sep 2023
				radiotherapy 20 Gy in 10 fractions+Durvalumab+Chemotherapy